Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL.
Manders SH, et al.
Arthritis Res Ther. 2015 May 22;17(1):134. doi: 10.1186/s13075-015-0630-5.
Arthritis Res Ther. 2015.
PMID: 25997746
Free PMC article.
Clinical Trial.
Cost-effectiveness was analysed on the basis of incremental net monetary benefit, which was based on quality-adjusted life-years (calculated using EQ-5D scores), and all medication expenditures consumed in 1 year. ...
Cost-effectiveness was analysed on the basis of incremental net monetary benefit, which was based on quality-adjusted life-years (calculated …